Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$86.72 USD

86.72
4,365,080

-0.64 (-0.73%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $86.73 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

3 Sell-Rated Drug Stocks Investors Should Avoid for Now

Despite a fairly upbeat performance of the pharma and biotech sector, caution has to be exercised before choosing a stock for investment as a few drug companies are struggling to revive business.

    Is Gilead Sciences (GILD) a Great Stock for Value Investors?

    Let's see if Gilead Sciences Inc. (GILD) stock is a good choice for value-oriented investors right now from multiple angles.

      Kevin Cook headshot

      Bull of the Day: Regeneron (REGN)

      Key pharma franchises in a bustling pipeline have shares looking attractive again at 17X and 15% EPS growth

        3 Biotech Stocks With Rising Earnings Estimates Post Q4

        The biotech industry performed reasonably well in Q4. Hence, it is a good idea to select stocks from the sector which saw positive estimate revisions post Q4 earnings release.

          Gilead Sciences (GILD) Down 3.4% Since Earnings Report: Can It Rebound?

          Gilead Sciences (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

            Biotech Stock Round Up: Regeneron Submits sBLA, Biogen to Withdraw Zinbryta

            The biotech sector was in focus last week with these stories - FDA's acceptance of Regeneron's Dupixent's application for asthma, Biogen and partner AbbVie's decision to withdraw multiple sclerosis drug among others.

              Gilead Announces Positive Data on New HIV Therapy Biktarvy

              Gilead (GILD) announces encouraging data from a phase III study, on its new HIV therapy, Biktarvy, at the 2018 Conference on Retroviruses and Opportunistic Infections in Boston.

                Biotech ETFs Head to Head: XBI vs. IBB.

                Head-to-head comparison of two Biotech ETFs, XBI and IBB.

                  The Zacks Analyst Blog Highlights: Gilead, BNY Mellon, State Street, Alliant Energy and Dillard's

                  The Zacks Analyst Blog Highlights: Gilead, BNY Mellon, State Street, Alliant Energy and Dillard's

                    Biotech Stock Round Up: Celgene Suffers Setback, Gilead Teams Up with Sangamo

                    The major news in the biotech sector in the last five trading sessions include the FDA's refusal to file letter for Celgene Corporation's (CELG) ozanimod while Gilead Sciences, Inc.'s (GILD) announced an agreement with Sangamo Therapeutics.

                      Mark Vickery headshot

                      Top Analyst Reports for Gilead, BNY Mellon & State Street

                      Today's Research Daily features new research reports on 12 major stocks, including Gilead (GILD), BNY Mellon (BK) and State Street (STT).

                        Intercept (ICPT) Q4 Earnings & Sales Lag on Dull Ocaliva

                        Intercept (ICPT) missed on both earnings and revenues in the fourth quarter as Ocaliva sales were drab due to safety issues of the drug.

                          Intercept Starts OCA Trial for NASH Patients With Cirrhosis

                          Intercept (ICPT) initiates a randomized phase III trial, REVERSE, on obeticholic acid in subjects with compensated cirrhosis due to non-alcoholic steatohepatitis.

                            Glaxo's (GSK) Begins Phase III HIV Two-Drug Regimen Study

                            Glaxo's (GSK) ViiV Healthcare commences phase III study on combo regimen of dolutegravir and lamivudine for maintenance of viral suppression in HIV-1 infection patients treated with TAF-based regimen.

                              Glaxo (GSK) Earnings and Revenues Surpass Estimates in Q4

                              Glaxo's (GSK) Q4 earnings and revenues beat estimates. In the event of Advair generic introduction in the U.S. market by mid 2018, Glaxo expects adjusted EPS to be flat to down at CER in 2018.

                                FDA Approves Gilead (GILD) HIV Triple Therapy, Stock Up

                                Gilead (GILD) gets a huge boost with the FDA's approval of its once-daily single tablet regimen (STR), Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF) for the treatment of HIV-1 infection.

                                  Gilead (GILD) Beats on Q4 Earnings, 2018 View Lacks Lustre

                                  Gilead (GILD) topped earnings and sales expectations in the fourth quarter but the guidance for 2018 was disappointing due to further weakness in the HCV franchise.

                                    The Zacks Analyst Blog Highlights: Walt Disney, Chipotle, Snap and Gilead Sciences

                                    The Zacks Analyst Blog Highlights: Walt Disney, Chipotle, Snap and Gilead Sciences

                                      Mark Vickery headshot

                                      New Quarterly Earnings Results for DIS, CMG, SNAP and More

                                      Will these companies reporting after the close -- DIS, CMG, SNAP and GILD -- catch a break in after-hours trading?

                                        Madeleine Johnson headshot

                                        Gilead (GILD) Posts Earnings Beat, Total Product Sales See YoY Decline

                                        Gilead Sciences (GILD) just released its fourth quarter fiscal 2017 financial results, posting earnings of $1.78 per share and revenues of $5.95 billion. Shares are down 2.4% to $78.50 in trading shortly after as a result.

                                          Gilead's (GILD) HCV Segment to Decline Further in Q4 Earnings?

                                          Gilead's HCV franchise is under significant pressure due to increasing competition and the decline in franchise sales is expected to impact fourth-quarter results.

                                            Will Gilead (GILD) Disappoint Investors in Q4 Earnings?

                                            Biotech bigwig Gilead Sciences (GILD) Q4 results are expected to be adversely impacted by the decline in HCV market share.

                                              Arpita Dutt headshot

                                              Biotech Stock Roundup: AbbVie 4Q Results Impress, Ablynx to be Acquired by Sanofi

                                              While companies like AbbVie (ABBV) were in focus on 4Q earnings results, Ablynx was in the news with the company agreeing to be acquired by French pharma giant, Sanofi.

                                                Celgene (CELG) Q4 Earnings & Sales Beat on Solid Revlimid

                                                Celgene's (CELG) fourth-quarter results beat on both sales and earnings driven by solid growth in Revlimid and pick up in Otezla sales after a slowdown.

                                                  Bluebird Up on Buyout Speculation After Celgene/Juno Deal

                                                  Bluebird Bio (BLUE) appears to be solid takeover target, with more and more companies expressing interest in the CAR-T space, especially after Celgene's acquisition of Juno Therapeutics.